China Universal Asset Management Co. Ltd. Acquires 16,764 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 64.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,787 shares of the company’s stock after purchasing an additional 16,764 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Sana Biotechnology were worth $178,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. increased its stake in Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after acquiring an additional 12,154 shares during the last quarter. Algert Global LLC bought a new position in Sana Biotechnology in the second quarter valued at approximately $73,000. Hartline Investment Corp bought a new position in Sana Biotechnology in the first quarter valued at approximately $136,000. XTX Topco Ltd bought a new position in Sana Biotechnology in the second quarter valued at approximately $100,000. Finally, Dark Forest Capital Management LP increased its stake in Sana Biotechnology by 112.0% in the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock valued at $149,000 after acquiring an additional 14,430 shares during the last quarter. 88.23% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. HC Wainwright cut their target price on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Citigroup lifted their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Sana Biotechnology Stock Down 3.2 %

SANA stock opened at $3.66 on Thursday. The firm has a market cap of $814.23 million, a price-to-earnings ratio of -3.18 and a beta of 1.42. Sana Biotechnology, Inc. has a 12-month low of $2.84 and a 12-month high of $12.00. The company’s fifty day simple moving average is $4.55 and its 200 day simple moving average is $6.02.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Research analysts expect that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.